You are being directed to ZacksTrade, a division of Zacks & Company and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
|No Recent Quote currently available|
My Portfolio Tracker
One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.
Dec 19, 2012 (Market movers via COMTEX) -- Omnicell (NASDAQ:OMCL), a company whose shares are moving quickly, is trading 1.5% higher to $16.05. The S&P is trading fractionally lower to 1,445 and the Dow is trading fractionally lower to 13,348.
There is potential upside of 10.1% for shares of Omnicell based on a current price of $16.05 and an average consensus analyst price target of $17.67. The stock should discover initial support at its 50-day moving average (MA) of $14.57 and subsequent support at its 200-day MA of $14.36.
Over the past year, Omnicell has traded in a range of $12.33 to $18.15 and is now at $16.05, 30% above that low. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 1.4%.
Omnicell, Inc. provides an integrated suite of clinical infrastructure and workflow automation solutions for healthcare facilities. The Company's solutions include pharmacy and supply systems, clinical reference tools, an Internet-based procurement application, and decision support tools. Omnicell sells and leases its products and services to a range of healthcare facilities.
Financial News Network Online (FNNO) is a leading provider of digital financial news content for distribution on the web. You can count on FNNO to bring you the latest market news, earnings reports, analyst comments, economic data reports and more. Visit http://www.fnno.com today.
Copyright, Comtex News Network, Inc. 2012
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Copyright 2014 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.